<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462641</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00130361</org_study_id>
    <secondary_id>R01NS099535</secondary_id>
    <nct_id>NCT03462641</nct_id>
  </id_info>
  <brief_title>Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm</brief_title>
  <official_title>Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This arm is a positron emission tomography (PET) biomechanistic GABA-A receptor target
      engagement study that includes detailed clinical and motor assessments before and after the
      i.v. administration of 1 mg flumazenil or placebo in Parkinson disease subjects. Each subject
      will receive 1mg flumazenil or placebo at two visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This biomechanistic GABA-A receptor target engagement study includes clinical and motor
      assessments before and at various time points up to approximately 90 minutes after the i.v.
      administration of 1 mg flumazenil and placebo in Parkinson disease subjects. Thirty Parkinson
      disease subjects with disease severity (Hoehn and Yahr) stages 2-4 will be recruited.
      Baseline [11C]FMZ and vesicular monoamine transporter type 2 (VMAT2) [11C]DTBZ brain PET
      imaging will be performed prior to drug administration to assess for GABA-A receptor
      availability and the integrity of nigrostriatal dopaminergic nerve terminals, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative biomechanics</measure>
    <time_frame>up to 3 hours (including pre- and post-infusion motor testing)</time_frame>
    <description>We will use the PIGD-UPDRS motor scale to assess axial motor functions before and after 1mg flumazenil iv and correlate this with the [11-Carbon]-flumazenil ([11C]FMZ) PET binding.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Flumazenil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flumazenil 1mg in 10cc normal saline will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 cc of normal saline placebo will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumazenil</intervention_name>
    <description>1mg in 10cc normal saline</description>
    <arm_group_label>Flumazenil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 cc normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parkinson's disease (PD): PD diagnosis will follow the UK Parkinson's Disease Society
             Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD.

          2. Hoehn and Yahr stages 2-4

          3. Absence of dementia confirmed by cognitive testing.

          4. Abnormal 11C-Dihydrotetrabenazine ([11C]-DTBZ) PET study to demonstrate nigrostriatal
             dopaminergic denervation.

        Exclusion Criteria:

          1. PD with Dementia (PDD) or dementia with Lewy bodies (DLB).

          2. Other disorders which may resemble PD, such as vascular dementia, normal pressure
             hydrocephalus, multiple system atrophy, corticobasal ganglionic degeneration, or toxic
             causes of parkinsonism. Prototypical cases have distinctive clinical profiles, like
             early and severe dysautonomia or appendicular apraxia, which may differentiate them
             from idiopathic PD. The use of the UKPDSBRC clinical diagnostic criteria for PD will
             mitigate the inclusion of subjects with atypical parkinsonism.

          3. Subjects on benzodiazepine, GABA-ergic medications (baclofen, tizanidine),
             neuroleptic, anticholinergic (trihexyphenidyl, benztropine), or cholinesterase
             inhibitor drugs.

          4. Evidence of a mass lesion on structural brain imaging (MRI).

          5. Participants in whom MRI is contraindicated including, but not limited to, those with
             a pacemaker, presence of metallic fragments near the eyes or spinal cord, chest, or
             cochlear implant.

          6. Severe claustrophobia precluding MR or PET imaging.

          7. Subjects limited by participation in research procedures involving ionizing radiation.

          8. Pregnancy (urine or serum pregnancy test within 48 hours of each PET session) or
             breastfeeding.

          9. History of seizures

         10. Significant anxiety or history of panic disorder.

         11. History of recent suicide attempt or overdose of tricyclic antidepressants or other
             medications

         12. Any other medical history determined by investigators to preclude safe participation.

         13. Allergy to flumazenil

         14. Significant liver disease

         15. History of alcohol or other substance abuse within past two years.

         16. History of regular benzodiazepine use within past year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas I Bohnen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Minderovic, BS</last_name>
    <phone>734-998-8400</phone>
    <email>cmindero@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Dowling, MD</last_name>
    <phone>734-998-8400</phone>
    <email>cdowling@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martijn Muller, Ph.D.</last_name>
      <phone>734-998-8400</phone>
      <email>mtmuller@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cyrus Sarosh, B.S.</last_name>
      <phone>734-998-8400</phone>
      <email>csarosh@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolaaas Bohnen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Nicolaas Bohnen, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Radiology and Neurology</investigator_title>
  </responsible_party>
  <keyword>Gait</keyword>
  <keyword>Balance</keyword>
  <keyword>Flumazenil</keyword>
  <keyword>PET Imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Mobility</keyword>
  <keyword>Intravenous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

